Illumina (NASDAQ:ILMN) has given its investors a late holiday present by releasing selected figures from its preliminary, unaudited Q4 results. For the quarter, company data shows that revenue came in at $387 million, which would top the average analyst estimate of $370 million.
The company also released guidance for its current fiscal 2014. It believes it will post a top line 15%-17% higher on a year-over-year basis, or roughly $1.54 billion to 1.57 billion against its anticipation of around $1.34 billion for fiscal 2013. Non-GAAP EPS for 2014 are anticipated at $2.00-$2.06 per diluted share. At the moment, the average analyst estimate for 2014 revenues is $1.6 billion, and for EPS it is $2.05.
On the back of consistently pleasing results, Illumina's shares have been on a steady rise over the past year, more than doubling to their present level of $121.51.
Fool contributor Eric Volkman has no position in Illumina. The Motley Fool recommends Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
What Happened in the Stock Market Today
On a record day for the indexes, Illumina stock rose on a product announcement and positive outlook, and e.l.f. Beauty fell following a lowered growth forecast.
5 Reasons Illumina Enjoyed a Big J.P. Morgan Conference Bounce
The gene-sequencing leader had plenty of good news to announce at the major healthcare conference this week.
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
Which stock wins in a head-to-head match-up between these two gene-sequencing leaders?